Chondrosarcomatous differentiation in metastatic deposit of serious papillary cystadenocarcinoma

Pathology International

Volumn 50, Issue 6, 2000, Pages 497-501

  Domoto, Hideharu ^a   Mano, Yoshinori ^b   Kita, Tsunekazu ^b   Kikuchi, Yoshihiro ^b   Sato, Kimiya ^b   Aida, Shinsuke ^b   Tamai, Seiichi ^b  

^a Undersea Medical Center   (Japan)

^b NONE

Author keywords

Carcinosarcoma; Chondrosarcoma; Malignant mixed mullerian tumor; Ovarian neoplasm; Serous papillary cystadenocarcinoma

Indexed keywords

ALPHA ACTIN; ANTIINFECTIVE AGENT; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN; CYTOKERATIN 20; CYTOKERATIN 7; EPITHELIAL MEMBRANE ANTIGEN; PROTEIN P53; PROTEIN S 100; VIMENTIN;

ADULT; ARTICLE; CANCER GROWTH; CANCER REGRESSION; CARCINOGENESIS; CASE REPORT; CHONDROSARCOMA; CYSTADENOCARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; TUMOR DIFFERENTIATION;

CA-15-3 ANTIGEN; CELL DIFFERENTIATION; CHONDROSARCOMA; CYSTADENOCARCINOMA, PAPILLARY; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; LYMPHATIC METASTASIS; MIDDLE AGED; OVARIAN NEOPLASMS; S100 PROTEINS; VIMENTIN;

EID: 0033927245     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1827.2000.01062.x     Document Type: Article

References (21)

1. 1 Rosai J. Ackerman's Surgical Pathology, 8th edn. Mosby, St Louis, 1996; 1461-1539.
2. 2 Barwick KW, LiVolsi VA. Malignant mixed mesodermal tumors of the ovary: A clinicopathologic assessment of 12 cases. Am. J. Surg. Pathol 1980; 4: 37-42.
3. 3 Morrow CP, d'Ablaing G, Brady LW, Blessing JA, Hreshchyshyn MM. A clinical and prognostic study of 30 cases of malignant mixed müllerian epithelial and mesenchymal ovarian tumors: A Gynecologic Oncology Group study. Gynecol. Oncol. 1984; 18: 278-292.
4. 4 Terada KY, Johnson TL, Hopkins M, Roberts JA. Clinicopathologic features of ovarian mixed mesodermal tumors and carcinosarcomas. Gynecol. Oncol. 1989; 32: 228-232.
5. 5 Boucher D, Tetu B. Morphologic prognostic factors of malignant mixed müllerian tumors of the ovary: A clinicopathologic study of 15 cases. Int. J. Gynecol. Pathol. 1994; 13: 22-28.
6. 6 Chang J, Sharpe JC, A'Hern RP et al. Carcinosarcoma of the ovary: Incidence, prognosis, treatment and survival of patients. Ann. Oncol. 1995; 6: 755-758.
7. 7 Dictor M. Malignant mixed mesodermal tumor of the ovary: A report of 22 cases. Obstet. Gynecol. 1985; 65: 720-724.
8. 8 Zaloudek C, Norris HJ. Mesenchymal tumors of the uterus. In: Kurman RJ, ed, Blaustein's Pathology of the Female Genital Tract. Springer-Verlag, New York, 1994; 487-528.
9. 9 Silverberg SG, Major FJ, Blessing JA et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int. J. Gynecol. Pathol. 1990; 9: 1-19.
10. 10 Meis JM, Lawrence WD. The immunohistochemical profile of malignant mixed müllerian tumor. Overlap with endometrial adenocarcinoma. Am. J. Clin. Pathol. 1990; 94: 1-7.
11. 11 Bitterman P, Chun B, Kurman RJ. The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am. J. Surg. Pathol. 1990; 14: 317-328.
12. 12 George E, Manivel JC, Dehner LP, Wick MR. Malignant mixed müllerian tumors: An immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum. Pathol. 1991; 22: 215-223.
13. 13 de Brito PA, Silverberg SG, Orenstein JM. Carcinosarcoma (malignant mixed müllerian (mesodermal) tumor) of the female genital tract: immunohistochemical and ultrastructural analysis of 28 cases. Hum. Pathol. 1993; 24: 132-142.
14. 14 Sreenan JJ, Hart WR. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am. J. Surg. Pathol. 1995; 19: 666-674.
15. 15 Costa MJ, Vogelsan J, Young LJ. p53 gene mutation in female genital tract carcinosarcomas (malignant mixed müllerian tumors): A clinicopathologic study of 74 cases. Mod. Pathol. 1994; 7: 619-627.
16. 16 Mayall P, Rutty K, Campell F, Goddard H. p53 immunostaining suggests that uterine carcinosarcomas are monoclonal. Histopathology 1994; 24: 211-214.
17. 17 Taylor CR, Shi SR, Chen C, Young C, Yang C, Cote RJ. Comparative study of antigen retrieval heating methods: microwave, microwave and pressure cooker, autoclave, and steamer. Biotech. Histochem. 1996; 71: 263-270.
18. 18 Hano H, Endo M, Sekino S, Takasaki S, Ushigome S. Malignant mixed müllerian tumor of the ovary. Report of a case studied by immunohistochemistry. Acta Pathol. Jpn. 1990; 40: 845-850.
19. 19 Chuang JT, Van Velden DJ, Graham JB. Carcinosarcoma and mixed mesodermal tumor of the uterine corpus. Review of 49 cases. Obstet. Gynecol. 1970; 35: 769-780.
20. 20 Costa MJ, Khan R, Judd R. Carcinoma (malignant mixed müllerian (mesodermal) tumor)) of the uterus and ovary. Correlation of clinical, pathologic, and immunohistochemical features in 29 cases. Arch. Pathol. Lab. Med. 1991; 115: 583-590.
21. 21 Gagne E, Tetu B, Blondeau L, Raymond PE, Blais R. Morphologic prognostic factors of malignant mixed müllerian tumor of the uterus: A clinicopathologic study of 58 cases. Mod. Pathol. 1989; 2: 433-438.